• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Scandidos

0.85 SEK+6.25 %10.7. klo 18.29
Less than 1K followers

SDOS

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+6.25 %
-1.73 %
-13.27 %
-28.57 %
-28.57 %
-39.29 %
-68.05 %
-77.86 %
-93.85 %

Scandidos operates in the medical technology sector. The company offers products and systems for quality assurance of advanced radiation therapy for cancer. The systems analyze the radiation dose before and during ongoing radiation treatment. The company was founded in 2002 and the first product was launched in 2006. Since its inception, Scandidos has delivered products to radiation therapy clinics on a global level. The head office is located in Uppsala.

Read more
Market cap
60.57M SEK
Turnover
206.69K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
17.9.
2026

Interim report Q1'27

21.10.
2026

General meeting '26

15.12.
2026

Interim report Q2'27

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release15.05.2026 klo 09.00

ScandiDos Unveils Delta4 SRS Pro at ESTRO 2026: Setting a New Standard for Stereotactic QA

Scandidos
Regulatory press release06.05.2026 klo 15.00

Anders Murman appointed Acting CEO of ScandiDos

Scandidos
Press release21.11.2024 klo 11.20

ScandiDos Expands with New Reference Center in Madrid, Spain

Scandidos

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release18.04.2024 klo 14.00

Successful user meeting in Madrid highlights ScandiDos' innovative solutions

Scandidos
Regulatory press release20.12.2023 klo 10.03

ScandiDos receives orders worth €478 000 from China

Scandidos
Regulatory press release30.11.2023 klo 09.15

ScandiDos AB changes Certified Adviser and liquidity provider to Carnegie Investment Bank AB (publ)

Scandidos
Regulatory press release29.11.2023 klo 17.34

ScandiDos achieves EU Medical Device Regulation certification for the Delta4 Phantom+ product line

Scandidos
Regulatory press release28.06.2023 klo 11.55

ScandiDos receives orders worth €290 000 from China

Scandidos
Press release13.05.2023 klo 11.00

ScandiDos and IBA Dosimetry deepen strategic alliance!

Scandidos
Regulatory press release14.03.2023 klo 14.00

ScandiDos receives an order worth €263 000 from China

Scandidos
Press release23.02.2023 klo 09.30

ScandiDos sees growing demand for patient-specific QA in Chinese market

Scandidos
Regulatory press release01.11.2022 klo 14.50

ScandiDos receives an order of € 377 500 from Japan

Scandidos
Press release02.09.2022 klo 15.30

ScandiDos’ directed share issue completed

Scandidos
Regulatory press release30.08.2022 klo 19.00

ScandiDos has completed a directed share issue of 4,150,000 shares at a subscription price of SEK 3 per share

Scandidos
Regulatory press release25.02.2022 klo 09.50

ScandiDos launches Delta4 Insight which is immediately available to sell to customers in Europe and parts of Asia.

Scandidos
Regulatory press release16.02.2022 klo 09.00

ScandiDos Celebrates 20th Anniversary

Scandidos
Regulatory press release04.03.2021 klo 17.36

ScandiDos: Leading centers all over the world select Scandidos' Delta4 Phantom+ MR for their MR-linac programs

Scandidos